Vertex, Inc. (NASDAQ:VERX) (“Vertex” or the “Company”), a global provider of tax technology solutions, was recognized on ...

The three-year partnership is another example of Vertex’s interest in improving on Casgevy, its CRISPR medicine for sickle ...

Orna will receive a $65m upfront payment and is eligible to receive potential milestone payments and royalties.

Vertex VERX shares have skyrocketed 107.3% in the past 12 months, outperforming the Zacks Computer Technology sector, Zacks Internet Software industry and the S&P 500’s return of 38.1%, 40.3% and 26.8 ...

The deal is set to help Vertex’s development of next-generation gene editing therapies for sickle cell disease and ...

Vertex is paying Orna $65 million upfront, in part via convertible note, according to a Jan. 7 release. Orna—which acquired ...

Vertex (VERX – Research Report) received a Hold rating and price target from Raymond James analyst Alexander Sklar today. The company’s ...

ClearBridge Investments, an investment management company, released its “ClearBridge Growth Strategy” fourth quarter 2024 ...

Vertex, Inc. (NASDAQ:VERX – Get Free Report) has received a consensus recommendation of “Moderate Buy” from the thirteen research firms that are covering the company, MarketBeat.com reports. Four ...

Hitachi Vantara, the data storage, infrastructure, and hybrid cloud management subsidiary of Hitachi, Ltd. (TSE: 6501), today announced that Malayala Manorama, India's second-largest newspaper by ...

Vertex Global Services partners with UK-based Arish Global Services to create over 5,000 jobs in India, boosting the ...

Vertex Pharmaceuticals Inc. will work with a Watertown biotech on new gene-editing therapies for people with sickle cell disease and transfusion-dependent beta thalassemia.